Your browser doesn't support javascript.
loading
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]. / Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d'un cancer épithélial de l'ovaire ¼ élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l'INCa ¼.
Lavoue, Vincent; Huchon, Cyrille; Akladios, Cherif; Alfonsi, Pascal; Bakrin, Naoual; Ballester, Marcos; Bendifallah, Sofiane; Bolze, Pierre-Adrien; Bonnet, Fabrice; Bourgin, Charlotte; Chabbert-Buffet, Nathalie; Collinet, Pierre; Courbiere, Blandine; De la Motte Rouge, Thibault; Devouassoux-Shisheboran, Mojgan; Falandry, Claire; Ferron, Gwenal; Fournier, Laure; Gladieff, Laurence; Golfier, François; Gouy, Sébastien; Guyon, Frédérique; Lambaudie, Eric; Leary, Alexandra; Lecuru, Fabrice; Lefrere-Belda, Marie-Aude; Leblanc, Eric; Lemoine, Adrien; Narducci, Fabrice; Ouldamer, Lobna; Pautier, Patricia; Planchamp, François; Pouget, Nicolas; Ray-Coquard, Isabelle; Rousset-Jablonski, Christine; Senechal-Davin, Claire; Touboul, Cyril; Thomassin-Naggara, Isabelle; Uzan, Catherine; You, Benoit; Daraï, Emile.
Affiliation
  • Lavoue V; CHU de Rennes, hôpital sud, service de gynécologie, 16, boulevard de Bulgarie, 35000 Rennes, France; Chemistry, oncogenesis, stress and signaling, centre Eugène Marquis, Inserm 1242, rue Bataille Flandres-Dunkerque, 35000 Rennes, France. Electronic address: Vincent.lavoue@chu-rennes.fr.
  • Huchon C; CHI Poissy, service de gynécologie, 78300 Poissy, France.
  • Akladios C; CHU Strasbourg, hôpital Hautepierre, service de gynécologie, 67000 Strasbourg, France.
  • Alfonsi P; Hôpital Saint-Joseph, service d'anesthésie, 75000 Paris, France.
  • Bakrin N; CHU Lyon-Sud, service de chirurgie digestive, Pierre-Bénite, 69000 Lyon, France.
  • Ballester M; Groupe hospitalier Diaconesses Croix Saint Simon, service de gynécologie, 75000 Paris, France.
  • Bendifallah S; AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.
  • Bolze PA; CHU Lyon-Sud, service de chirurgie gynécologique, Pierre Bénite, 69000 Lyon, France.
  • Bonnet F; AP-HP, hôpital Tenon, service d'anesthésie, 75020 Tenon, France.
  • Bourgin C; CHRU, hôpital Jeanne de Flandres, service de chirurgie gynécologique, 59000 Lille, France.
  • Chabbert-Buffet N; AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.
  • Collinet P; CHRU, hôpital Jeanne de Flandres, service de chirurgie gynécologique, 59000 Lille, France.
  • Courbiere B; AP-HM La Conception, pôle Femmes-Parents-Enfants-centre clinico-biologique d'AMP, 147, boulevard Baille, 13000 Marseille, France; Aix-Marseille université, CNRS, IRD, Avignon université, IMBE UMR 7263, 13000 Marseille, France.
  • De la Motte Rouge T; Centre Eugène Marquis, service d'oncologie médicale, 35000 Rennes, France.
  • Devouassoux-Shisheboran M; CHU Lyon-Sud, service d'anatomo-pathologie, hospices civiles de Lyon, Pierre-Bénite, 69000 Lyon, France.
  • Falandry C; CHU Lyon-Sud, service d'oncogériatrie, hospices civiles de Lyon, Pierre-Bénite, 69000 Lyon, France.
  • Ferron G; Institut Claudius Regaud, IUCT Oncopole, service d'oncologie chirurgicale, 31000 Toulouse, France.
  • Fournier L; AP-HP, service de radiologie, hôpital Européen Georges Pompidou, 75015 Paris, France.
  • Gladieff L; Institut Claudius Regaud, IUCT Oncopole, service d'oncologie médicale, 31000 Toulouse, France.
  • Golfier F; CHU Lyon-Sud, service de chirurgie gynécologique, Pierre Bénite, 69000 Lyon, France.
  • Gouy S; Institut Gustave Roussy, service de chirurgie, 94800 Villejuif, France.
  • Guyon F; Institut Bergonié, service de chirurgie, 33000 Bordeaux, France.
  • Lambaudie E; Institut Paoli Calmette, service de chirurgie, 13000 Marseille, France.
  • Leary A; Institut Gustave Roussy, service d'oncologie médicale, 94800 Villejuif, France.
  • Lecuru F; AP-HP, hôpital Européen Georges Pompidou, service de chirurgie gynécologique et oncologique, 75015 Paris, France.
  • Lefrere-Belda MA; AP-HP, hôpital Européen Georges Pompidou, service d'anatomo-pathologie, 75015 Paris, France.
  • Leblanc E; Centre Oscar Lambret, service de chirurgie, 59000 Lille, France.
  • Lemoine A; AP-HP, hôpital Tenon, service d'anesthésie, 75020 Tenon, France.
  • Narducci F; Centre Oscar Lambret, service de chirurgie, 59000 Lille, France.
  • Ouldamer L; CHU de Tours, service de chirurgie gynécologique, 37000 Tours, France.
  • Pautier P; Institut Gustave Roussy, service d'oncologie médicale, 94800 Villejuif, France.
  • Planchamp F; Institut Bergonié, service de méthodologie, 33000 Bordeaux, France.
  • Pouget N; Curie (site Saint Cloud), service de chirurgie, 75000 Paris, France.
  • Ray-Coquard I; Centre Léon Bérard, service d'oncologie médicale, 69000 Lyon, France.
  • Rousset-Jablonski C; Centre Léon Bérard, service d'oncologie médicale, 69000 Lyon, France.
  • Senechal-Davin C; Institut Bergonié, service de chirurgie, 33000 Bordeaux, France.
  • Touboul C; CHI de Créteil, service de chirurgie gynécologique, 94000 Créteil, France.
  • Thomassin-Naggara I; AP-HP, hôpital Tenon, service de radiologie, 75020 Tenon, France.
  • Uzan C; Institut universitaire de cancérologie, Sorbonne université, hôpital Pitié-Salpêtrière, service de chirurgie et cancérologie gynécologique et mammaire, Inserm U938, 75000 La pitié, France.
  • You B; Institut de cancérologie des Hospices Civils de Lyon, service d'oncologie médicale, Pierre-Bénite, 69000 Lyon, France.
  • Daraï E; AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.
Bull Cancer ; 106(4): 354-370, 2019 Apr.
Article in Fr | MEDLINE | ID: mdl-30850152
Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Fallopian Tube Neoplasms / Carcinoma, Ovarian Epithelial Type of study: Diagnostic_studies / Guideline Country/Region as subject: Europa Language: Fr Journal: Bull Cancer Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Fallopian Tube Neoplasms / Carcinoma, Ovarian Epithelial Type of study: Diagnostic_studies / Guideline Country/Region as subject: Europa Language: Fr Journal: Bull Cancer Year: 2019 Type: Article